Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial
Katherine R Tuttle(University of Washington), Mark Lakshmanan(Eli Lilly (United States)), Brian Rayner(University of Cape Town), Robert S. Busch(Albany Medical Center Hospital), Alan G. Zimmermann(Eli Lilly (United States)), D. Bradley Woodward(Eli Lilly (United States)), Fady T. Botros(Eli Lilly (United States))
Cited by 631
Abstract
Related Papers
No related papers found
Powered by citation graph analysis